Article
Immunology
Gabriele Sass, Julianne J. Marsh, Pallabi Shrestha, Raquel Sabino, David A. Stevens
Summary: Cystic fibrosis patients frequently suffer from co-infections of Pseudomonas aeruginosa and Aspergillus fumigatus, which can cause airway inflammation and worsen lung function. Recent studies have shown that P. aeruginosa interacts synergistically with the antifungal drug voriconazole, inhibiting A. fumigatus biofilm metabolism. This interaction is mediated by several molecules, including pyoverdine. Clinical isolates of P. aeruginosa from CF patients show varying degrees of interaction with voriconazole, suggesting that lower concentrations of the drug might be sufficient to control fungal growth during co-infections.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Immunology
Kelly Kweng, Andrea Benedetti, Yvonne Yau, Valerie Waters, Dao Nguyen
Summary: This study found that PA isolates from new-onset CF infections exhibit strain-specific susceptibility to neutrophil antibacterial functions, and PA isolates resistant to neutrophil phagocytosis are independent risk factors for failed tobramycin eradication. Experimental results on neutrophil phagocytosis and intracellular killing showed that isolates from persistent infections were more resistant compared to those from eradicated infections.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Respiratory System
Lindsay Jackson, Valerie Waters
Summary: Considerable advancements have been made in extending the life expectancy of cystic fibrosis patients, but chronic Pseudomonas aeruginosa infections remain a threat. Standard antibiotic eradication therapies targeting P. aeruginosa fail in a significant percentage of patients, with reasons for failure still not fully understood.
JOURNAL OF CYSTIC FIBROSIS
(2021)
Article
Respiratory System
Isabel Gascon Casaredi, Michelle Shaw, Valerie Waters, Ryan Seeto, Ana C. Blanchard, Felix Ratjen
Summary: This study conducted long-term follow-up observation on cystic fibrosis patients and found that antibiotic eradication therapy (AET) can improve lung function in patients with early Pseudomonas aeruginosa infection.
JOURNAL OF CYSTIC FIBROSIS
(2023)
Article
Biotechnology & Applied Microbiology
Rachith Kalgudi, Roya Tamimi, Godfrey Kyazze, Tajalli Keshavarz
Summary: The study revealed that the combined use of farnesol and tyrosol had a better effect on Pseudomonas aeruginosa biofilm growth, especially against the RBHi strain, while the addition of quorum quenchers (QQs) reduced IL-8 secretion by A549 cells.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
(2021)
Article
Pediatrics
Birce Sunman, Nagehan Emiralioglu, Gulsen Hazirolan, Burcin Sener, Beste Ozsezen, Dilber A. Tural, Halime N. Buyuksahin, Ismail Guzelkas, Ebru Yalcin, Deniz Dogru, Ugur Ozcelik, Nural Kiper
Summary: This study compares the effectiveness of intravenous therapy and inhalation therapy with/without oral therapy in eradicating new-onset Pseudomonas aeruginosa in children with cystic fibrosis, and assesses the impact on lung function. The results indicate that there is no advantage of intravenous therapy in terms of eradication success.
PEDIATRIC PULMONOLOGY
(2022)
Review
Microbiology
Christina S. Thornton, Michael G. Surette
Summary: Cystic fibrosis is the most common and lethal genetic disease among the Caucasian population, leading to chronic airway inflammation and declining pulmonary function. Studies have shown a diverse community of anaerobic bacteria in CF patients' airways, potentially impacting disease progression through synergistic interaction with principal pathogens. Despite the understanding of this complex bacterial milieu, the specific roles of anaerobes in disease progression remain unclear.
JOURNAL OF CLINICAL MICROBIOLOGY
(2021)
Article
Microbiology
Xuerui Bao, Mona Bove, Tom Coenye
Summary: The high tolerance of Pseudomonas aeruginosa biofilms in respiratory tract infections in cystic fibrosis contributes to the failure of antibiotic therapy. This study identified carbon sources that could enhance the inhibiting and/or eradicating activity of tobramycin, ciprofloxacin, and ceftazidime against P. aeruginosa PAO1 biofilms. The mechanisms underlying the enhanced biofilm eradicating activity were strain-dependent.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Immunology
Veronica Roxana Flores-Vega, Silvia Yalid Vargas-Roldan, Jose Luis Lezana-Fernandez, Ricardo Lascurain, Jose Ignacio Santos-Preciado, Roberto Rosales-Reyes
Summary: Cystic fibrosis is a genetic disease caused by a mutation in the cftr gene, affecting chloride ion and water transport and leading to bacterial infections in the lungs. Autophagy plays a crucial role in pathogen clearance, but P. aeruginosa and B. cenocepacia have strategies to evade this pathway, resulting in chronic inflammatory immune responses.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Immunology
Dirk Westhoelter, Jonas Raspe, Hendrik Uebner, Johannes Pipping, Mona Schmitz, Svenja Strassburg, Sivagurunathan Sutharsan, Matthias Welsner, Christian Taube, Sebastian Reuter
Summary: The study found that treatment with elexacaftor/tezacaftor/ivacaftor can increase the percentage of Tregs, especially in CF patients clearing Pseudomonas aeruginosa infection. This suggests that targeting Treg homeostasis is a therapeutic option for CF patients with persistent Treg impairment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Jonathan D. Cogen, Anna Faino, Frankline Onchiri, Lucas R. Hoffman, Matthew P. Kronman, David P. Nichols, Margaret Rosenfeld, Ronald L. Gibson
Summary: A retrospective cohort study found that there were no significant differences in respiratory and clinical outcomes between young patients with cystic fibrosis treated with one versus two intravenous antipseudomonal antibiotics for pulmonary exacerbations.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Immunology
Buqing Yi, Alexander H. Dalpke, Sebastien Boutin
Summary: The development of CFTR modulator therapies has significantly changed the treatment scheme of people with cystic fibrosis, but further research is needed to understand the effects of such modulation on the airway microbiome for managing airway infections effectively.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Giovanni Di Bonaventura, Veronica Lupetti, Simone De Fabritiis, Alessandra Piccirilli, Annamaria Porreca, Marta Di Nicola, Arianna Pompilio
Summary: This study evaluated the antibacterial and antivirulence activities of eight FDA-approved non-antibiotic drugs and their effects on biofilm formation. Ciclopirox and actinomycin D showed the best antibacterial activity and were most effective against preformed biofilms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pediatrics
H. Hakan Mursaloglu, Can Akin, Cansu Yilmaz Yegit, Almala P. Ergenekon, Burcu Suzer Uzunoglu, Gamze Tastan, Yasemin Gokdemir, Ela Erdem Eralp, Aysegul Karahasan Yagci, Fazilet Karakoc, Bulent Karadag
Summary: In patients with chronic pulmonary infection in CF, there was no significant difference in outcomes between IV and non-IV treatment regimens for eradicating PA and MRSA. Non-parenteral eradication may be a better option considering cost-effectiveness and treatment burden.
PEDIATRIC PULMONOLOGY
(2021)
Editorial Material
Medicine, Research & Experimental
Roberto Rosales-Reyes, Veronica Roxana Flores-Vega, Jose Luis Lezana-Fernandez, Jose Ignacio Santos-Preciado
Summary: Pseudomonas aeruginosa is a significant pathogen causing lung infections in patients with cystic fibrosis. Its increasing antibiotic resistance makes treatment challenging. Microbiology and whole genome sequencing are important tools for determining antimicrobial susceptibility and resistance as well as analyzing genomic variations. Molecular epidemiologic surveillance aids in developing better treatment strategies and controlling the spread of Pseudomonas aeruginosa variants.
ARCHIVES OF MEDICAL RESEARCH
(2022)